Alyeska Investment Group’s AbCellera Biologics ABCL Stock Holding History

Alyeska Investment Group’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.13M	Sell	526,577 -2,065,528	-80%	-$10.1M	0.01%	522
2026 Q1	$9.05M	Buy	+2,592,105	New	+$9.33M	0.03%	415
2023 Q4	–	Sell	-501,355	Closed	-$2.31M	–	511
2023 Q3	$2.31M	Buy	+501,355	New	+$3.05M	0.02%	382
2023 Q1	–	Sell	-100,000	Closed	-$1.01M	–	442
2022 Q4	$1.01M	Buy	+100,000	New	+$1.16M	0.01%	347
2022 Q3	–	Sell	-746,652	Closed	-$7.95M	–	378
2022 Q2	$7.95M	Sell	746,652 -985,160	-57%	-$8.34M	0.09%	237
2022 Q1	$16.9M	Buy	1,731,812 +314,449	+22%	+$2.98M	0.19%	161
2021 Q4	$20.3M	Buy	1,417,363 +1,345,543	+1,873%	+$20.4M	0.23%	131
2021 Q3	$1.44M	Sell	71,820 -153,180	-68%	-$2.71M	0.02%	556
2021 Q2	$4.95M	Buy	225,000 +25,000	+13%	+$689K	0.06%	351
2021 Q1	$6.79M	Sell	200,000 -50,000	-20%	-$1.99M	0.09%	270
2020 Q4	$10.1M	Buy	+250,000	New	+$11.4M	0.14%	198

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Alyeska Investment Group's ABCL Position: Q2 2026 in Review

Alyeska Investment Group reduced its AbCellera Biologics (ABCL) stake by 80% in Q2 2026, selling an estimated $10.1M and leaving 526,577 shares worth $4.13M. The position accounts for 0.01% of the portfolio, ranked #522.

Alyeska Investment Group first reported a position in ABCL in Q4 2020 and has held it in 11 quarters since. The position peaked at $20.3M in Q4 2021. 151 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

Alyeska Investment Group held 526,577 shares of AbCellera Biologics worth $4.13M as of Q2 2026.
Alyeska Investment Group sold 2,065,528 AbCellera Biologics shares in Q2 2026, an estimated $10.1M.
AbCellera Biologics made up 0.01% of Alyeska Investment Group's portfolio in Q2 2026, its #522 holding.
Alyeska Investment Group first reported a position in AbCellera Biologics in Q4 2020 and has held it in 11 quarters since.
Alyeska Investment Group's AbCellera Biologics position peaked at $20.3M in Q4 2021.
151 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Alyeska Investment Group's 13F filing for Q2 2026, filed 14 Aug 2026.